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ABSTRACT
Isolated isochromosome 17q, i(17q), accounts for less than 1% of myeloid 
neoplasms that are commonly classified as myelodysplastic/myeloproliferative 
neoplasms, acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) or 
myeloproliferative neoplasms (MPN). We have shown previously that these cases 
have distinctive clinicopathologic features, a poor prognosis and absence of TP53 
mutations. However, their molecular mutation profile has not been studied. Here, we 
explored the mutation profile of 32 cases of myeloid neoplasm with isolated i(17q) 
that included AML, MDS/MPN, MDS and MPN. In addition to the common i(17q), 
these neoplasms had frequent mutations in SRSF2 (55%), SETBP1 (59%), ASXL1 
(55%), and NRAS (31%); TET2 and TP53 mutations were rare. Eight of 28 patients 
(29%) showed concurrent mutations in ASXL1, SRSF2, SETBP1 and RAS. There was 
a significant association between mutations in SETBP1 and RAS (p = 0.003). The 
mutation pattern was independent of the morphologic diagnosis. Sequential analysis 
of 5 cases showed evolution from a diploid karyotype to i(17q) and that SRSF2 and 
ASXL1 mutations precede the detection of i(17q) whereas SETBP1 mutations are 
associated with i(17q).
INTRODUCTION 
Isochromosome 17q [i(17q)] is a non-random 
cytogenetic abnormality that involves deletion of the short 
“p” arm and duplication of the long “q” arm of chromosome 
17. It is frequently observed in the setting of a complex 
karyotype in blast phase of chronic myelogenous leukemia 
(CML) and acute myeloid leukemia (AML). As an isolated 
cytogenetic abnormality, isochromosome (17q) in myeloid 
malignancies is rare with less than 150 reported cases. 
The presence of isolated i(17q) in myeloid neoplasms is 
associated with certain distinctive clinicopathologic findings 
as shown in several recent studies [1–3]. These neoplasms 
are often classified as myelodysplastic/myeloproliferative 
neoplasms (MDS/MPN) or high-grade myelodysplastic 
syndrome (MDS)/ AML, and show characteristic 
morphologic findings, in particular pseudo Pelger-Huet 
neutrophils and small hypolobated megakaryocytes. 
Irrespective of the diagnosis or blast count at presentation, 
myeloid neoplasms with isolated i(17q) have an aggressive 
clinical course. Most patients undergo rapid progression 
to AML, often without acquisition of additional clonal 
cytogenetic abnormalities. Accordingly, i(17q) is classified 
as “intermediate” cytogenetic prognostic subgroup per 
the revised International Prognostic Scoring System 
(IPSS) for MDS [4, 5]; and as an “adverse” cytogenetic 
prognostic subgroup per revised Medical Research Council 
classification for AML [6]. 
Understanding the molecular alterations in myeloid 
neoplasms associated i(17q) will likely prove to be valuable 
Oncotarget14252www.impactjournals.com/oncotarget
in the development of targeted therapy for affected patients. 
The “low-copy repeats” rich breakpoint region, located at 
17p11.2 is highly unstable and prone to be affected by large-
scale genomic alterations including uniallelic loss of TP53 
[7, 8]. Until now, studies have shown that the presence of 
i(17q) abnormality is associated with wild-type TP53 [1] 
and mutations in SETBP1 and SRSF2 [3, 9]. However, the 
molecular consequences of i(17q) are largely unknown. 
Further, it is unclear if the i(17q) abnormality precedes these 
gene mutations or represents a secondary event. 
In this study, we performed a systematic molecular 
analysis of myeloid neoplasms with isolated i(17q) and 
discovered unique molecular alterations that provide insights 
into underlying pathogenesis and potential therapeutic 
targets. Using sequential mutation analysis in 5 cases that 
showed evolution of i(17q) abnormality from a diploid 
karyotype, we show that SRSF2 and ASXL1 mutations 
precede the detection of i(17q), whereas SETBP1 mutations 
are associated with i(17q). 
RESULTS 
We selected 32 cases of myeloid neoplasm with i(17q) 
as the primary abnormality that had sufficient DNA for 
molecular analysis. This group included 13 cases of MDS/
MPN, 17 cases of AML (5 of which had a history of myeloid 
neoplasm), and 1 case each of MDS and MPN (clinical data 
shown in Table 1). Twenty-nine cases had i(17q) as a sole 
abnormality (2 acquired +13 subsequently during the course 
of the disease), 2 had 1 additional abnormality and 1 had 
multiple additional abnormalities. All cases were negative 
for BCR/ABL1 rearrangement. 
We analyzed three cases with isolated i(17q) using 
whole-exome sequencing and found mutations in genes 
that included SETBP1, SRSF2, and ASXL1 (Supplementary 
Table 1). We performed mutation analysis of 33 genes using 
a combination of next-generation sequencing based analysis 
on all 32 cases targeting the coding regions of 28 genes; 
and Sanger sequencing for splicing factors, CEBPA, MDM4 
and SETBP1. The mutation results are shown in Figure 1. 
The details are provided in Supplementary Table 2. The 
median number of mutations per sample was 3. Genes 
with the highest frequency of mutations included: SETBP1 
(17/29; 59%), ASXL1 (17/31; 55%), SRSF2 (16/29; 55%), 
and NRAS (10/32; 31%). Mutations in genes that directly 
affect the RAS pathway was noted in 18 (56%) cases and 
included: NRAS (n = 10, 31%), PTPN11 (n = 4; 13%), KRAS 
(n = 3; 9%), and HRAS (n = 1; 3%). These four mutations 
were mutually exclusive with each other, and in all but 
1 case, they were exclusive with other genes affecting 
RAS/MAPK signaling pathway including EGFR, FLT3, 
KIT, and BRAF, but not SETBP1. There was a significant 
association between mutations in SETBP1 and RAS 
(p = 0.003). There was a trend towards association between 
mutations in SETBP1 and SRSF2 (p = 0.07); and SETBP1 
and ASXL1 (p = 0.07). Eight of 28 patients (29%) showed 
concurrent mutations in ASXL1, SRSF2, SETBP1 and RAS. 
Ten patients (35%) showed concurrent mutations in SRSF2, 
SETBP1 and RAS. Notably, mutations in TET2, TP53 and 
U2AF1 were rare. SF3B1 mutations were absent. SETBP1 
and TP53 mutations were mutually exclusive as reported 
by others [3, 9, 10] except in 1 case where TP53 mutation 
was observed at 5% variant allelic frequency (VAF) in a 
post allogeneic stem cell transplant setting. In addition to 
the findings shown in Figure 1, none of the tested cases had 
mutations in CEBPA (n = 15) or MDM4 (n = 12). 
Segregation of genes based on the functional 
classification per Cancer Genome Atlas Research Network 
showed that mutations occurred in highest frequencies in 
genes involved in activating signaling pathways (mostly 
RAS), followed by splicing factor-encoding and epigenetic 
modifier genes (Supplementary Figure 1) [11]. Of the 4 
most frequently mutated genes, VAF could be estimated 
for the genes of RAS pathway and ASXL1 as these were 
analyzed by NGS. The median VAF of NRAS and ASXL1 
mutations in our cohort were 41.7 (range, 5–49.2) and 
32.8 (range, 6–72) respectively. Eleven cases showed 
mutations in both RAS and ASXL1. In 8 of these cases, 
the VAF of RAS mutation was either similar to or higher 
than of ASXL1. The VAFs of SETBP1 and SRSF2 could 
only be assessed in 3 cases that underwent whole exome 
sequencing. The results showed that all mutated genes had 
a similar VAF in all cases. 
The median overall survival (OS) from the onset of 
disease was 22.1 months, and median OS from the onset 
of i(17q) was 9.4 months (Kaplan-Meier curves shown 
in Supplementary Figure 3). There were no apparent 
differences in the mutation profile between the cases of 
AML and MDS/MPN, although the numbers are too small 
for significance. 
Within this study cohort, 5 cases had an initial 
diploid karyotype and subsequently acquired i(17q). We 
performed mutation analysis on these patients at various 
time points during the evolution from diploid to karyotype 
showing i(17q) (as shown in Figure 2). Within the interval 
between the initial analysis to the development of i(17q) 
abnormality, all patients had undergone treatment with 
drugs that included decitabine, Ruxolitinib, hydroxyurea, 
dasatinib and lenalidomide. In one case, the i(17q) 
abnormality was acquired post-allogeneic stem cell 
transplantation. Mutations in ASXL1, SRSF2 and RAS 
appear stable over time. ASXL1 mutations were present in 
all 5 cases at both diploid and i(17q) stages of karyotypic 
evolution. SRSF2 mutations were also present at both 
diploid and i(17q) stages in 3 of 5 patients. Mutations 
in NRAS (n = 2) and PTPN11 (n = 1) at high allelic 
frequencies (> 35%) were also stable, being present at 
the diploid and i(17q) stages. In 3 patients, additional 
mutations were observed at the time of i(17q) abnormality. 
These mutations occurred in SETBP1 (n = 2), KRAS 
(n = 1, subclonal, 7%) and TP53 (n = 1, subclonal, 5%; 
post allogeneic stem cell transplant) genes. The only 
case that showed SETBP1 mutation at the time of diploid 
karytoype developed i(17q) within 5 months. 
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DISCUSSION
Myeloid neoplasms associated with isolated 
i(17q) show characteristic clinicopathologic features 
and aggressive behavior. In order to study molecular 
aberrations associated with the presence of i(17q), and to 
exclude the confounding effects of additional karyotypic 
aberrations, we included cases showing i(17q) as a sole 
karyotypic abnormality and performed a comprehensive 
mutational analysis. The genes with the highest mutation 
frequency included ASXL1, SRSF2, SETBP1 and RAS 
signaling pathway genes, noted in more than 50% of the 
samples. In most of our cases, RAS mutations were detected 
at high allelic frequencies with a median of 42.1%. We 
performed pyrosequencing on majority of cases to confirm 
RAS mutations. These results have clinical implications 
because patients with myeloid neoplasms associated with 
i(17q) have a poor outcome and RAS and splicing factor 
mutations provide potential targets for treatment. 
We also observed a high frequency of ASXL1, 
SETBP1 and SRSF2 mutations in myeloid neoplasms 
associated with i(17q). Similar observations were presented 
by Meggendorfer et al. at the 2015 ASH meeting (abstract# 
1656; session: 636. Myelodysplastic Syndromes – Basic 
and Translational Studies: Poster I) [12]. However, the 
frequency of RAS mutations reported by the authors 
was much lower. This discordance may be related to the 
differences in the patient cohort, as their study included 
63 patients, of which only 27 had isolated i(17q). The 
remainder of patients in their study had additional 
abnormalities including some patients with a complex 
karyotype. 
Mutations in ASXL1 (3/9, 33%), SRSF2 (3/9, 33%), 
and SETBP1 (5/9, 56%) were also observed in de novo AML 
Table 1: Summary of clinicopathologic and cytogenetic findings of 32 myeloid neoplasms with 
isolated i(17q) cytogenetic abnormality 
Variable MDS/MPN 
(n = 13, 41%) AML (n = 17, 53%)
MDS 
(n = 1, 3%)
MPN 
(n = 1, 3%)  
Median age (range) 64 years (51–83) 66 years (24–78) 55 years 60 years
Gender (female/male) 9/4 8/9 0/1 0/1
Hemoglobin* (g/dL) 9.4 (6.8–12.1) 10.1 (6.4–12.8) 8.6 12.9
MCV 88 (78–102) 88 (70–110) 91.5 104
Absolute neutrophil count*, × 109/L 3.6 (0.5–122.2) 3.0 (0–24.2) 1.9 5.7
Platelet count*, × 109/L 54 (10–143) 57 (15–271) 92 141
Peripheral blood blasts* (%) 1 (0–13) 26 (0–97) 0 1
Bone marrow blasts* (%) 8 (2–19) 37 (7–93) 12 0
Cytogenetic evolution, n (%)  30.8% 23.5%
Without clonal evolution 9 13 0 1
With clonal evolution 4 4 1 0
Survival 12 died, 1 lost to follow-up 
14 died, 1 alive, 2 lost to 
follow-up Died Died 
2008 WHO sub-classification 
CMML (n = 6) 
MDS/MPN-U (n = 5) 
aCML (n = 2) 
De novo/ AML MRC 
(n = 9); sAML: h/o 
myeloid neoplasm 
(n = 5) and therapy-
related (n = 2); AML, 
relapsed post-allogeneic 
SCT, unclassifiable 
(n = 1)
RAEB-2 Post-ET MF 
aCML, atypical chronic myeloid leukemia;  AML, acute myeloid leukemia; AML MRC, AML with myelodysplasia-related 
changes; CMML, chronic myelomonocytic leukemia; MCV, mean corpuscular volume; MDS, myelodysplastic syndrome; 
MDS/MPN-U, myelodysplastic/ myeloproliferative neoplasm unclassifiable; Post-Et MF, Post-essential thrombocythemia 
myelofibrosis; RAEB, refractory anemia with excess blasts; sAML, secondary AML; SCT, stem cell transplant. 
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Figure 1: Mutational analysis of 32 cases of myeloid neoplasm with isolated i(17q) (red, mutation; gray, wild-type; 
white, not tested). Genes are segregated based on the biologic functional categories on the left. The upper panels denote the case number, 
diagnostic categories per 2008 WHO classification and clonal cytogenetic abnormalities. Case #31 could not be sub-classified. Isochromosome 
(17q) was detected on a post-allogeneic stem cell transplant sample that showed relapsed AML. The pre-transplant cytogenetic studies were 
diploid, and molecular studies were unavailable. The patient also had a history of breast carcinoma treated with chemotherapy. Cases 7, 9 
and 31 (highlighted in lavender) also underwent whole-exome sequencing. *represents a non-R882 DNMT3A mutation. aCML, atypical 
chronic myeloid leukemia; AML, acute myeloid leukemia; AML MRC, AML with myelodysplasia-related changes; CMML, chronic 
myelomonocytic leukemia; ET, Essential thrombocythemia; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm; MDS/
MPN, myelodysplastic/myeloproliferative neoplasm; MDS/MPN-U, myelodysplastic/myeloproliferative neoplasm unclassifiable; MF, 
myelofibrosis; RAEB, refractory anemia with excess blasts; sAML, secondary AML; SCT, stem cell transplant.
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cases (n = 9). Lindsley et al. have shown that mutations in 
ASXL1 and splicing factors, as observed in our cohort, are 
highly specific for secondary AML [13]. Gene mutations 
in NPM1, DNMT3A, CEBPA, IDH1 and FLT3, that are 
reportedly common in de novo AML, were infrequent. 
Thus, the presence of i(17q) may indicate an underlying 
MDS or MDS/MPN, at least in a subset of AML cases, even 
in de novo setting. The only case with an NPM1 mutation 
was a patient with relapsed AML status post allogeneic 
stem cell transplant. The patient had a history of breast 
carcinoma treated with chemotherapy and AML with a 
diploid karyotype. Cytogenetic studies showed i(17q) in 7 
of 20 metaphases. In the presence of NPM1 mutation, i(17q) 
abnormality may have been transiently acquired due to the 
damaging effects of chemotherapy. 
Another notable finding in our study was the rarity 
of mutations in TET2 and other genes involved in DNA 
methylation pathway. Our cohort included 13 MDS/MPN 
cases and 4 AML cases with a prior history of MDS/MPN. 
TET2 mutations are highly prevalent in cases of aCML, 
CMML and MDS/MPN unclassifiable (41%, 62% and 
26% respectively) as shown by several authors, although 
these studies have not looked into cases with isolated i(17q) 
abnormality in particular [14–25]. 
A limitation of our study is the low detection 
sensitivity of Sanger sequencing used for assessment of 
SRSF2 and SETBP1. The Sanger sequencing technique 
has a detection sensitivity of 10–20%, compared to NGS-
based assay (5%). Hence, the mutational frequencies 
of SRSF2 and SETBP1 may be underestimated in our 
results. A strength of this study is that it is the first study 
to perform sequential mutational analysis of patients over 
the course of karyotypic progression, from diploid to 
i(17q). The findings in these 5 patients suggest that ASXL1, 
SRSF2 and RAS pathway gene mutations occur prior to 
i(17q). In a subset of cases, SETBP1 mutation may be 
associated with the development of i(17q) abnormality in 
these neoplasms. Interestingly, we found 1 patient with a 
history of primary myelofibrosis who transiently acquired 
i(17q) abnormality. This abnormality was present in 4/20 
and 1/20 metaphases (confirmed by uniallelic TP53 by 
FISH), at two different time points, 6 months apart. Bone 
marrow morphology showed myelofibrosis associated 
with trilineage dysplasia and monocytosis. Subsequently, 
the i(17q) abnormality disappeared (also confirmed by 
array based comparative hybridization and FISH studies), 
and the patient acquired del(3)(q12q24) and trisomy 8. 
The mutation profile remained the same. NGS sequencing 
based mutation analysis at 3 different time points showed 
mutations in JAK2, ASXL1 and KRAS; SRSF2 and SETBP1 
were wild-type (Figure 2). These results support that i(17q) 
abnormality is associated with mutated SRSF2 and SETBP1.
Our results provide insights into the molecular 
consequences of i(17q), which leads to the obligatory 
loss of a single TP53 allele located at 17p13.1 [7]. We 
have confirmed that TP53 mutations, even at low allelic 
frequencies, are exceedingly rare in myeloid neoplasms 
with isolated i(17q) using next-generation sequencing 
based mutation analysis. This finding suggests involvement 
by mechanisms other than TP53 mutation-induced genomic 
instability [1, 3, 9] [10]. Alternatively, TP53 dysfunction 
may be the result of copy number changes or alterations in 
RNA and protein expression of other molecules of TP53 
pathway that have not been explored. At the same time, a 
potential role for several hematopoiesis-related candidate 
genes on 17q has not been explored. These genes include 
NF1, RARA, G-CSF, MPO, ERBB2, and BRCA1 genes 
and miRNAs. Of note, SRSF2 located at 17q25.1 was 
mutated in 55% cases in this study. SRSF2 P95 mutation 
is a gain-of-function mutation that causes alterations in the 
binding affinity of SRSF2 to a number of target pre-mRNA 
transcripts thereby affecting alternative splicing and gene 
Figure 2: Sequential mutation analysis of myeloid neoplasms during the evolution from a diploid karyotype to the 
development of isolated i(17q) abnormality. In case #5, i(17q) was observed after allogeneic stem cell transplant. In case #6, i(17q) 
abnormality was transient (noted for only a duration of 6 months).
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expression [26]. Sequential mutational analysis suggests 
that SRSF2 mutation, along with ASXL1, occurs early 
during the disease, and is present at the time the karyotype 
is diploid. In these cases, the formation of i(17q) leads to 
a higher dosage of mutant SRSF2 and alterations of gene 
expression on a larger scale. The combination of SRSF2 and 
ASXL1 mutations, together with mutations in SETBP1 may 
contribute to the dismal outcome. 
In summary, we have performed a comprehensive 
gene mutational analysis in the largest series of myeloid 
neoplasms with isolated i(17q) abnormality to date. Our 
results show a high frequency of mutations in SRSF2, 
SETBP1, ASXL1 and NRAS genes. In cases where isolated 
i(17q) abnormality was acquired during the disease course, 
SRSF2 and ASXL1 mutations preceded i(17q) detection, 
whereas SETBP1 mutations were associated with i(17q). 
The acquisition of i(17q) abnormality and the presence 
of these adverse molecular markers may contribute to the 
poorer outcome of these patients. SRSF2 and RAS pathway 
gene mutations may be potential therapeutic targets for 
aggressive management of these neoplasms. 
MATERIALS AND METHODS
Patient cohort 
This study was approved by the institutional review 
board. Informed consent was obtained from all patients. 
We retrieved all cases of myeloid neoplasm with i(17q) 
as the primary cytogenetic abnormality from our database 
from 1998–2014. Clinical data was collected from the 
medical records. All relevant pathology material including 
peripheral blood, bone marrow smears and biopsy sections, 
and immunocytochemical stains were reviewed. All cases 
were classified according to the 2008 WHO classification. 
Cytogenetic analysis 
Conventional cytogenetic studies were performed 
on metaphase cells prepared from bone marrow aspirate 
smears using standard techniques. The results were 
reported using the International System for Human 
Cytogenetic Nomenclature (2009 and 2013). 
Genetic analysis 
We performed amplicon-based next-generation 
sequencing (NGS) targeting the coding regions of a panel 
of 28 genes implicated in myeloid neoplasms using MiSeq 
platform (Illumina, San Diego, CA) on archived DNA 
extracted from fresh bone marrow aspirate samples. We 
used 250 ng of DNA to prepare the genomic library. The 
genes included in this panel are as follows: ABL1, ASXL1, 
BRAF, DNMT3A, FGFR, EZH2, FLT3, GATA1, GATA2, 
HRAS, IDH1, IDH2, IKZF2, JAK2, KIT, KRAS, MDM2, 
MLL, MPL, MYD88, NOTCH1, NPM1, NRAS, PTPN11, 
RUNX1, TET2, TP53, and WT1. Following successful 
library generation and purification, equal quantities of 
DNA from each sample were used for multiplex paired-end 
sequencing on MiSeq personal genome sequencer using 
the MiSeq Reagent Kit v2 (500 cycles). Human genome 
build 19 (hg19) was used as the reference for sequence 
alignment. MiSeq Reporter Software 2.2 and Integrative 
Genomics Viewer (IGV) were used for variant calling 
and visualization respectively. Successful sequencing 
was indicated by a Q30 score of more than 85%. For this 
study, variants with more than 5% allelic frequency with 
a minimum coverage of 250X in both directions were 
included. Since matched normal tissue was not tested, 
data from literature and COSMIC database was used to 
infer somatic nature. Single nucleotide polymorphisms 
listed in dbSNP 137 and 138 and 10K genome project 
were excluded. The functional significance of all variants 
was analyzed using PolyPhen-2 website (http://genetics.
bwh.harvard.edu/pph2/); only variants that resulted in 
“probably damaging” were included. Selected variants 
were confirmed using an alternate platform, such as Sanger 
sequencing, pyrosequencing or capillary electrophoresis 
(data not shown). Mutation analyses of 5 additional genes 
that are not included in the NGS panel (SETBP1, CEBPA, 
MDM4, and splicing factor genes SRSF2, SF3B1 and 
U2AF1) were performed by Sanger sequencing. In 25 cases, 
FLT3 mutational analysis for internal tandem duplication 
was also performed by capillary electrophoresis. 
Statistical analysis 
Frequencies and percentages were calculated for 
categorical variables, and means and standard deviation 
were calculated for continuous variables. Fisher’s exact 
test was used to assess the association between categorical 
variables and mutation rate (not corrected for multiple 
testing). All statistical analyses were performed using SAS 
9.3 for Windows.
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